TBI is associated with significantly reduced DTI-ALPS values, with more prominent deteriorations over the long term, supporting its potential as a biomarker of glymphatic impairment. However, methodological heterogeneity emphasizes the need for standardized protocols and longitudinal studies to establish clinical utility.
Lomer et al. (Tue,) studied this question.